EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor–Positive, Early-Stage Breast Cancer

Mariana Chavez-MacGregor iD, Jieling Miao iD, Lajos Pusztai iD, Matthew P Goetz iD, Priya Rastogi iD, Patricia A Ganz iD, Eleftherios P Mamounas iD, Soonmyung Paik iD, Hanna Bandos, Wajeeha Razaq, Anne O'Dea, Virginia Kaklamani iD und 10 weitere

Journal of Clinical Oncology · 2024-09 · 42 (25) · 3012-3021

DOI: 10.1200/jco.23.02344 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Journal of Clinical Oncology, 2024-09. Verfasst von Mariana Chavez-MacGregor und 21 weiteren Autor:innen. Beteiligte Einrichtung: The University of Texas MD Anderson Cancer Center, Houston, TX. Hauptthemen laut MEDLINE: Everolimus, Breast Neoplasms. Die Arbeit wurde bisher 19-mal zitiert (Crossref) und nennt 38 Literaturangaben. Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: NCI NIH HHS, NCATS NIH HHS.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE Phosphatidylinositol 3-kinase/AKT-serine threonine kinase/mammalian target of rapamycin (mTOR) pathway abnormalities contribute to endocrine resistance. Everolimus, an mTOR inhibitor, improved progression-free survival in hormone receptor–positive metastatic breast cancer (BC) when combined with endocrine therapy (ET). In this phase III randomized, placebo-controlled trial, we assessed the efficacy of everolimus + ET as adjuvant therapy in high-risk, hormone receptor–positive, human epidermal growth factor receptor 2–negative BC after adjuvant/neoadjuvant chemotherapy. METHODS Patients were randomly assigned 1:1 to physician's choice ET and 1 year of everolimus (10 mg orally once daily) or placebo stratified by risk group. The primary end point was invasive disease-free survival (IDFS) evaluated by a stratified log-rank test with the hazard ratio (HR) estimated by Cox regression. Subset analyses included preplanned evaluation by risk group and exploratory analyses by menopausal status and age. Secondary end points included overall survival (OS) and safety. Everolimus did not improve IDFS/OS when added to ET in patients with early-stage high-risk, hormone receptor–positive BC. RESULTS One thousand and nine hundred thirty-nine patients were randomly assigned with 1,792 eligible for analysis. Overall, no benefit of everolimus was seen for IDFS (HR, 0.94 [95% CI, 0.77 to 1.14]) or OS (HR, 0.97 [95% CI, 0.75 to 1.26]). The assumption of proportional hazards was not met suggesting significant variability in the HR over time since the start of treatment. In an unplanned subgroup analysis among postmenopausal patients (N = 1,221), no difference in IDFS (HR, 1.08 [95% CI, 0.86 to 1.36]) or OS (HR, 1.19 [95% CI, 0.89 to 1.60]) was seen. In premenopausal patients (N = 571), everolimus improved both IDFS (HR, 0.64 [95% CI, 0.44 to 0.94]) and OS (HR, 0.49 [95% CI, 0.28 to 0.86]). Treatment completion rates were lower in the everolimus arm compared with placebo (48% v 73%) with higher grade 3 and 4 adverse events (35% v 7%). CONCLUSION One year of adjuvant everolimus + ET did not improve overall outcomes. Subset analysis suggests mTOR inhibition as a possible target for patients who remain premenopausal after chemotherapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

EverolimusBreast NeoplasmsHumansFemaleMiddle AgedAgedAdultAntineoplastic Combined Chemotherapy ProtocolsReceptors, EstrogenErb-b2 Receptor Tyrosine KinasesReceptors, ProgesteroneNeoplasm StagingChemotherapy, AdjuvantAntineoplastic Agents, Hormonal

Substanzen

EverolimusReceptors, EstrogenErb-b2 Receptor Tyrosine KinasesReceptors, ProgesteroneAntineoplastic Agents, Hormonal

Autor:innen und Institutionen

  • The University of Texas MD Anderson Cancer Center, Houston, TX.
  • SWOG Statistical Center, Seattle, WA.
  • Yale University Cancer Center, New Haven, CT.
  • Alliance, Mayo Clinic Comprehensive Cancer Center, Rochester, MN.
  • NRG Oncology, University of Pittsburgh, Pittsburgh, PA.
  • NRG Oncology, UCLA Jonsson Comprehensive Cancer Center, Los Angeles, CA.

ORCID-Profile: Mariana Chavez-MacGregor, Jieling Miao, Lajos Pusztai, Matthew P Goetz, Priya Rastogi, Patricia A Ganz, Eleftherios P Mamounas, Soonmyung Paik, Virginia Kaklamani, Andrea L M Silber, Jennifer F Carney, Priyanka Sharma, Julie R Gralow, William E Barlow, Gabriel N Hortobagyi

Förderung

  • NCI NIH HHS
  • NCATS NIH HHS

Zitieren

APA

Chavez-MacGregor, M., Miao, J., Pusztai, L., Goetz, M. P., Rastogi, P., Ganz, P. A., Mamounas, E. P., Paik, S., Bandos, H., Razaq, W., O'Dea, A., Kaklamani, V., Silber, A. L. M., Flaum, L. E., Andreopoulou, E., Wendt, A. G., Carney, J. F., Sharma, P., Gralow, J. R., …, & Hortobagyi, G. N. (2024). Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor–Positive, Early-Stage Breast Cancer. Journal of Clinical Oncology, 42(25), 3012-3021. https://doi.org/10.1200/jco.23.02344

Vancouver

Chavez-MacGregor M, Miao J, Pusztai L, Goetz MP, Rastogi P, Ganz PA, et al. Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor–Positive, Early-Stage Breast Cancer. Journal of Clinical Oncology. 2024;42(25):3012-3021. doi:10.1200/jco.23.02344

BibTeX
@article{ChavezMacGregor2024,
  author = {Chavez-MacGregor, Mariana and Miao, Jieling and Pusztai, Lajos and Goetz, Matthew P and Rastogi, Priya and Ganz, Patricia A and Mamounas, Eleftherios P and Paik, Soonmyung and Bandos, Hanna and Razaq, Wajeeha and O'Dea, Anne and Kaklamani, Virginia and Silber, Andrea L M and Flaum, Lisa E and Andreopoulou, Eleni and Wendt, Albert G and Carney, Jennifer F and Sharma, Priyanka and Gralow, Julie R and Lew, Danika L and Barlow, William E and Hortobagyi, Gabriel N},
  title = {Phase III Randomized, Placebo-Controlled Trial of Endocrine Therapy ± 1 Year of Everolimus in Patients With High-Risk, Hormone Receptor–Positive, Early-Stage Breast Cancer},
  journal = {Journal of Clinical Oncology},
  year = {2024},
  volume = {42},
  number = {25},
  pages = {3012--3021},
  doi = {10.1200/jco.23.02344}
}
Kostenlos starten →